FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and is associated with the diagnosis and treatment of malignant tumours, more specifically to a diagnostic technique for the presence of malignant tumour metastases by plasma detection of Hsp90α, having amino acid sequence SEQ ID NO: 1, as a tumour marker.
EFFECT: in addition, the present invention is also related to a method of treating a malignant tumour and metastases.
19 cl, 20 dwg, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| EXO-SOMATIC BIOMARKERS | 2015 |
|
RU2712223C2 |
| COMPOSITIONS OF IMMUNOGENIC/THERAPEUTIC GLYCOCONJUGATES AND USE THEREOF | 2015 |
|
RU2720295C2 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| DRUG CONJUGATES CONTAINING ANTI-CLAUDIN 18.2 ANTIBODIES | 2016 |
|
RU2841168C2 |
| ADENOVIRUSES AND METHODS FOR ADENOVIRUS APPLICATION | 2019 |
|
RU2782528C1 |
| ANTI-CEACAM6 ANTIBODIES AND USE THEREOF | 2016 |
|
RU2739163C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH BRAF ATYPICAL MUTATIONS | 2018 |
|
RU2812706C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2019 |
|
RU2781542C2 |
